

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

### Complete if Known

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/575,132       |
| Filing Date            | July 7, 2006     |
| First Named Inventor   | Sarah Donald     |
| Art Unit               | 1612             |
| Examiner Name          | Chris E. Simmons |
| Attorney Docket Number | 13566.105014     |

### U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|---------------------|----------|--|--------------------------------|--|---|
|                     |          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                     |          |  |                                |  |   |
|                     |          |  |                                |  |   |
|                     |          |  |                                |  |   |
|                     |          |  |                                |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>3</sup> |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
|                    |                       | Country Code <sup>3</sup> , Number <sup>2</sup> , Kind Code <sup>3</sup><br>(if known) |                                |   |  |                |
|                    |                       | WO 03/020259   | 03-13-2003                     | Cancer<br>Research<br>Technology<br>Limited           |  |                |
|                    |                       |  |                                |   |  |                |
|                    |                       |  |                                |   |  |                |
|                    |                       |  |                                |   |  |                |
|                    |                       |  |                                |   |  |                |
|                    |                       |  |                                |   |  |                |
|                    |                       |  |                                |   |  |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>1</sup> See Kind Code of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 501.04. <sup>2</sup> Enter Office that issued the document, by the locational code (WIPO Standard ST 3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>5</sup> If it is possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/575,132       |
| Filing Date            | July 7, 2006     |
| First Named Inventor   | Sarah Donald     |
| Art Unit               | 1612             |
| Examiner Name          | Chris E. Simmons |
| Attorney Docket Number | 13566.105014     |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|                                 |                       | Alexopoulos, "Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer," Ann. Oncol., 2004, 15(6):891-5  |                |
|                                 |                       | D'Incalci et al., "Unique Features of the Mode of Action of ET-743", The Oncologist, 7, p. 210-216, June 2002   |                |
|                                 |                       | Donald et al, "Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro," Cancer Chemother Pharmacol, April 2004, vol. 53, pp. 305-12   |                |
|                                 |                       | European Medicines Agency (EMA), "Scientific Discussion" from the European Public Assessment Report for Yondelis®, Revision 1, published March 31, 2008, downloaded from the internet on April 2, 2008, from the website<br><< <a href="http://www.emea.europa.eu/humandocs/Humans/EPAR/yondelis/yondelis.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/yondelis/yondelis.htm</a> >> |                |
|                                 |                       | Forouzesht et al., Proc. Am. Soc. Clin. Oncol. ASCO meeting, Abstract 373, June 3, 2001, Internet Archive Entry from the website<br><< <a href="http://web.archive.org/web/http://www.asco.org/">http://web.archive.org/web/http://www.asco.org/</a> >>, 32 pages   |                |
|                                 |                       | Gourley C. et al., "Malignant mixed Mesodermal Tumours - Biology and Clinical Aspects," European Journal of Cancer, 2002, vol. 38, no. 11, pages 1437-1446  |                |
|                                 |                       | Halm et al., "A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma," Ann. Oncol., 2000, 11(1):113-114   |                |
|                                 |                       | Hoekman et al., "A phase I/II study of dose-escalated docetaxel given two weekly in combination with a fixed dose of G-CSF," European Journal of Cancer, vol. 37, page S76, Abstract 270, October 22, 2001  |                |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/575,132       |
| Filing Date            | July 7, 2006     |
| First Named Inventor   | Sarah Donald     |
| Art Unit               | 1612             |
| Examiner Name          | Chris E. Simmons |
| Attorney Docket Number | 13566.105014     |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|----------|---|----------------|
|                     |          | Horstmann et al., "Risks and Benefits of Phase I Oncology Trials, 1991 through 2002," New England Journal of Medicine, vol. 352, pages 895-904; March 3, 2005   |                |
|                     |          | Lau et al., "A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors." Clinical Cancer Research, vol. 11, pp. 672-677, Jan. 15, 2005   |                |
|                     |          | PR Newswire, PR Newswire, October 14, 2001, 4 pages   |                |
|                     |          | Puchalski et al., "Pharmacokinetics of Ecteinascidin 743 Administered as a 24-h Continuous Intravenous Infusion to Adult Patients with Soft Tissue Sarcomas associations with Clinical Characteristics, Pathophysiological Variables and Toxicity," Cancer Chemotherapy and Pharmacology, 2002, vol. 50, no. 4, pages 309-319 |                |
|                     |          | Rote Liste 2002 "Doxorubicin," entries 86-056 through 86-062, 2002  |                |
|                     |          | Sarosy et al., "Phase I Study of $\alpha 2$ -interferon plus Doxorubicin in Patients with Solid Tumors," Cancer Research, vol. 46, pp. 5368-5371, 1986  |                |
|                     |          | Schwartzmann G. et al., "Marine Organisms as a Source of New Anticancer Agents," The Lancet Oncology, 2001, vol. 2, no. 4, pages 221-225  |                |
|                     |          | Twelves et al., "Phase I and pharmacokinetic study of YondelisTM (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours," European Journal of Cancer, vol. 39, p. 1842-1851, 2003; available online August 14, 2003   |                |
|                     |          | Wollina, "Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma," Cancer 2003, 1:98(5):993-1001, published online July 24, 2003   |                |

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.